• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Biote Announces CEO Retirement and Succession Plan

    1/30/25 4:10:00 PM ET
    $BTMD
    $HOLX
    $MYGN
    $PODD
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical Electronics
    Health Care
    Get the next $BTMD alert in real time by email

    Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors

    Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director

    biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executive Officer and Director, effective February 1, 2025.

    "On behalf of the Board, I want to thank Terry for her many contributions to Biote's success over the past six years. Under Terry's leadership, Biote has grown to become one of the nation's leading educators in hormone optimization, with over 7,000 Biote-certified practitioners advancing patient health and well-being throughout the country," said Marc Beer, Executive Chairman of the Board of Directors. "Terry's passionate commitment to women's health has been invaluable in enabling Biote to redefine the concept of healthy aging, and we believe her strategic vision has positioned Biote for continued growth in the years ahead."

    Ms. Weber commented, "It has been my profound honor to grow Biote over the past six years while building Biote's best-in-class practitioner network and advancing the cause of women's health. I am proud of Biote's continued efforts to initiate essential conversations that I believe will enhance health care industry practices and policies long-term. I look forward to collaborating with Bret and the Board as Biote further expands access to transformative healthcare solutions."

    Mr. Christensen is a distinguished executive with over two decades of leadership experience in women's health and the broader health care sector. Throughout his career, Mr. Christensen has consistently worked to advance health care offerings into industry standards, demonstrating an outstanding ability to launch innovative solutions, penetrate markets and effectively scale businesses.

    "On behalf of the Board of Directors, I am delighted to welcome Bret to Biote," Mr. Beer said. "In his prior commercial and general management leadership roles at Hologic (NASDAQ:HOLX), Myriad Genetics (NASDAQ:MYGN) and Insulet (NASDAQ:PODD), Bret helped revolutionize treatments in women's health care, oncology and diabetes, generating profitable growth and achieving significant commercial success of numerous products. With his deep expertise spanning the diagnostic, therapeutic and medical device health care sectors, we believe Bret is exceptionally qualified to lead Biote's next level of growth and help drive value creation for Biote stakeholders."

    Mr. Christensen said, "I am excited to join Biote at this pivotal time as the Company continues to build on its success in hormone optimization while capturing the complementary growth opportunity in therapeutic wellness. With an unparalleled technology, training and education platform, I believe Biote is uniquely positioned to deliver impactful wellness services and products to an expanding universe of practitioners and patients and achieve accelerated growth."

    About Biote

    Biote is transforming healthy aging through innovative, personalized hormone optimization and therapeutic wellness solutions delivered by Biote-certified medical providers. Biote trains practitioners to identify and treat early indicators of aging conditions, an underserved global market, providing affordable symptom relief for patients and driving clinic success for practitioners.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words "may," "can," "should," "will," "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "hope," "believe," "seek," "target," "continue," "could," "might," "ongoing," "potential," "predict," "would" and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers' reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers' sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the implementation of our growth strategies; our limited operating history; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including the impact of hurricane and other natural disasters; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and other risks and uncertainties described in the "Risk Factors" section of the Biote's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024, filed with the Securities and Exchange Commission on November 12, 2024, and other documents filed by Biote from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250130813030/en/

    Investor Relations:

    Eric Prouty

    AdvisIRy Partners

    [email protected]

    Media:

    [email protected]

    Get the next $BTMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTMD
    $HOLX
    $MYGN
    $PODD

    CompanyDatePrice TargetRatingAnalyst
    Insulet Corporation
    $PODD
    10/21/2025$370.00Buy
    Stifel
    Hologic Inc.
    $HOLX
    10/7/2025$78.00In-line → Outperform
    Evercore ISI
    Insulet Corporation
    $PODD
    9/8/2025$365.00Outperform
    Oppenheimer
    Hologic Inc.
    $HOLX
    8/18/2025$80.00Hold → Buy
    Argus
    Biote Corp.
    $BTMD
    8/7/2025$4.00Buy → Neutral
    B. Riley Securities
    Hologic Inc.
    $HOLX
    8/6/2025$87.00Sector Perform → Outperform
    RBC Capital Mkts
    Hologic Inc.
    $HOLX
    7/9/2025$80.00Neutral → Buy
    Citigroup
    Insulet Corporation
    $PODD
    6/16/2025$365.00Buy
    Truist
    More analyst ratings

    $BTMD
    $HOLX
    $MYGN
    $PODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Insulet with a new price target

    Stifel resumed coverage of Insulet with a rating of Buy and set a new price target of $370.00

    10/21/25 7:21:42 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Hologic upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Hologic from In-line to Outperform and set a new price target of $78.00

    10/7/25 8:47:36 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Oppenheimer resumed coverage on Insulet with a new price target

    Oppenheimer resumed coverage of Insulet with a rating of Outperform and set a new price target of $365.00

    9/8/25 8:52:38 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $BTMD
    $HOLX
    $MYGN
    $PODD
    SEC Filings

    View All

    Insulet Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INSULET CORP (0001145197) (Filer)

    10/23/25 7:18:45 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Hologic Inc.

    DEFA14A - HOLOGIC INC (0000859737) (Filer)

    10/21/25 5:01:23 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form DEFA14A filed by Hologic Inc.

    DEFA14A - HOLOGIC INC (0000859737) (Filer)

    10/21/25 5:00:57 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $BTMD
    $HOLX
    $MYGN
    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Madaus Martin D bought $300,760 worth of shares (5,445 units at $55.24) (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    5/9/25 4:39:33 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Large owner Guines Llc bought $1,461,373 worth of shares (447,714 units at $3.26) (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    5/8/25 7:16:54 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Guines Llc bought $6,371 worth of shares (1,933 units at $3.30) (SEC Form 4)

    4 - biote Corp. (0001819253) (Issuer)

    5/2/25 5:12:33 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTMD
    $HOLX
    $MYGN
    $PODD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Insulet Announces Appointment of Robert L. Huffines to its Board of Directors

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Robert ("Robbie") L. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., to the Company's board of directors, effective October 31, 2025. Mr. Huffines joins the board as an independent director and will serve on the board's Audit Committee. "We are honored to welcome Robbie to Insulet's Board of Directors," said Timothy Scannell, Chairman of the Board. "Robbie brings more than three decades of distinguished experience advising healthcare companies at one of the world's leading f

    10/23/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Biote Schedules Third Quarter 2025 Financial Results Release and Conference Call

    biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Wednesday, November 5, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast w

    10/22/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Hologic to be Acquired by Blackstone and TPG for up to $79 per Share

    Hologic Stockholders to Receive $76 per Share in Cash Plus a Contingent Value Right of up to $3 per Share Payable Upon Achieving Certain Revenue Milestones Represents 46% Premium to Hologic's Closing Price on Last Trading Day Prior to Media Reports of Possible Transaction Transaction Includes Significant Minority Investments from ADIA and GIC Transaction Will Help Hologic Strengthen its Leadership in Women's Health and Accelerate Growth Hologic, Inc. (NASDAQ:HOLX) today announced that it has entered into a definitive agreement to be acquired by funds managed by Blackstone ("Blackstone") and TPG in a transaction valued at up to $79 per share, representing an enterprise value of up to

    10/21/25 8:41:00 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $BTMD
    $HOLX
    $MYGN
    $PODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stamoulis Christiana exercised 7,402 shares at a strike of $36.04 and sold $540,864 worth of shares (7,402 units at $73.07) (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    10/22/25 4:17:40 PM ET
    $HOLX
    Medical Electronics
    Health Care

    EVP & CFO Pease Flavia was granted 11,708 shares, increasing direct ownership by 323% to 15,337 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    10/2/25 4:19:14 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Chairman, President and CEO Macmillan Stephen P sold $9,266,118 worth of shares (138,358 units at $66.97) and exercised 138,358 shares at a strike of $39.96 (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    9/23/25 4:10:08 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $BTMD
    $HOLX
    $MYGN
    $PODD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 29, 2024 - FDA Roundup: October 29, 2024

    For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod

    10/29/24 3:30:19 PM ET
    $HOLX
    Medical Electronics
    Health Care

    February 2, 2024 - FDA Roundup: February 2, 2024

    For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump

    2/2/24 3:58:21 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $BTMD
    $HOLX
    $MYGN
    $PODD
    Leadership Updates

    Live Leadership Updates

    View All

    Insulet Announces Appointment of Robert L. Huffines to its Board of Directors

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Robert ("Robbie") L. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., to the Company's board of directors, effective October 31, 2025. Mr. Huffines joins the board as an independent director and will serve on the board's Audit Committee. "We are honored to welcome Robbie to Insulet's Board of Directors," said Timothy Scannell, Chairman of the Board. "Robbie brings more than three decades of distinguished experience advising healthcare companies at one of the world's leading f

    10/23/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet to Host Investor Day on November 20, 2025

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's Acton, Massachusetts headquarters on Thursday, November 20, 2025. The Investor Day will include presentations from the management team highlighting the Company's longer-term strategic priorities, including market opportunities, innovation roadmap, as well as its longer-term financial outlook. Manufacturing tours will be available following the conclusion of the formal presentations, which are expected to begin at 9:00 a.m. (ET) and conclude at approximately 12:30 p.m. (ET). The Company invites in

    10/10/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Announces CFO Transition

    Flavia Pease Appointed Chief Financial Officer Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Flavia Pease will succeed Ana Maria Chadwick as Executive Vice President, Chief Financial Officer, effective September 30, 2025. Ms. Chadwick will become a Senior Advisor to Insulet to ensure a smooth transition. "I want to personally thank Ana, who has provided steady and thoughtful leadership for Insulet during a period of significant growth," said Ashley McEvoy, Insulet President and Chief Executive Officer. "She has been instrumental in strengthening our financial

    9/16/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $BTMD
    $HOLX
    $MYGN
    $PODD
    Financials

    Live finance-specific insights

    View All

    Biote Schedules Third Quarter 2025 Financial Results Release and Conference Call

    biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Wednesday, November 5, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast w

    10/22/25 4:05:00 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025

    Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2025 on Monday, November 3, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing 800-330-6710 (in the United States and Canada) or +1 312-471-1353 (for international callers) and referencing access code 5756948. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.hologic.

    10/2/25 4:04:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)

    Raising Full Year Revenue and Adjusted Operating Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025. Second Quarter Financial Highlights: Revenue of $649.1 million, up 32.9%, or 31.3% in constant currency, exceeds the high end of the Company's guidance range of 26.0% in constant currency Total Omnipod revenue of $639.0 million, up 33.0%, or 31.4% in constant currency U.S. Omnipod revenue of $453.2 million, up 28.7% International Omnipod revenue of $185.8 million, up 45.0%, or 38.8% in cons

    8/7/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $BTMD
    $HOLX
    $MYGN
    $PODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

    SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)

    11/14/24 4:16:31 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hologic Inc.

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    11/14/24 1:28:29 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biote Corp.

    SC 13G/A - biote Corp. (0001819253) (Subject)

    11/12/24 4:15:18 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care